On Monday, BMO Capital Markets sustained its optimistic stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $160.00 price target for the company's stock. The affirmation follows the latest phase 2a trial results for Monlunabant, a weight loss drug under development by Novo Nordisk.
According to BMO's analysis, the trial demonstrated a notable 5.8% placebo-adjusted weight loss at 16 weeks, a result that surpasses the performance of previous CB1 receptor antagonists at the 52-week mark. The analysis highlighted that while the efficacy of Monlunabant was strong, increasing the dosage beyond 10mg did not yield significant additional benefits.
The trial also reported an imbalance in mild to moderate psychiatric side effects, which has been a point of concern in the assessment. However, BMO noted that there were no serious neuropsychiatric adverse events, a factor that contributed to their continued endorsement of the drug's potential.
BMO's commentary on the trial underscored that Monlunabant is still in the early phase of clinical testing and is not the primary element driving their positive thesis on Novo Nordisk. The firm's outlook remains favorable, with the anticipation that further development could support the drug's success in the market.
The maintained price target of $160.00 reflects BMO's confidence in Novo Nordisk's pipeline and the expected performance of its various pharmaceutical products, including Monlunabant. The company's shares continue to be watched by investors as the clinical trials progress.
In other recent news, Novo Nordisk, a Danish pharmaceutical company, has been facing mixed outcomes in its development of obesity treatment drugs. Despite disappointing results from the Phase II obesity trial of monlunabant, which demonstrated a weight loss of approximately 6-7% at the 16-week mark, TD Cowen maintained its Buy rating on the company's shares. BMO Capital Markets also sustained its Outperform rating for Novo Nordisk, in light of the mixed trial results.
Furthermore, Novo Nordisk's drug amycretin showed promising weight loss results in a Phase 1 study, leading Cantor Fitzgerald to maintain its Overweight rating on the company's shares. However, the company also faces challenges with counterfeit Ozempic pens circulating globally, which pose significant health risks.
In other developments, the 5th U.S. Circuit Court of Appeals has revived a lawsuit challenging the U.S. law mandating drug price negotiations for Medicare, a program that serves 66 million individuals. This could potentially impact Novo Nordisk, as its diabetes medication, Ozempic, is under scrutiny by Wall Street analysts for potential inclusion in the 2027 Medicare price negotiations. Despite this, Novo Nordisk, among other drugmakers, does not anticipate a substantial impact on their businesses when the new prices come into effect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.